Alumis (ALMS) Cash from Operations (2023 - 2025)
Alumis (ALMS) posted quarterly Cash from Operations of 71884000.0 for Q4 2025, up 3.85% year-over-year from 69217652.05 in Q4 2024, and up 35.19% quarter-over-quarter from 110916000.0 in Q3 2025.
Alumis (ALMS) Cash from Operations (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Cash from Operations for 3 consecutive years, with 71884000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 3.85% year-over-year to 71884000.0; the TTM figure through Dec 2025 stood at 369500000.0 (down 44.86% YoY), while the FY2025 annual figure was 369500000.0, down 44.86% from the prior year.
- Cash from Operations improved to 71884000.0 in Q4 2025 per ALMS's latest filing, from 110916000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 33198000.0 in Q3 2023 and bottomed at 110916000.0 in Q3 2025.
- Historically, Cash from Operations has averaged 69157600.0 across 3 years, with a median of 73324000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 152.32% — and 2025, when it gained 3.85%.
- Alumis' Cash from Operations stood at 33800000.0 in 2023, then tumbled by 121.2% to 74764000.0 in 2024, then increased by 3.85% to 71884000.0 in 2025.
- Business Quant data shows ALMS's Cash from Operations at 71884000.0 in Q4 2025, 110916000.0 in Q3 2025, and 106300000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -71.88 Mn |
| Dec 31, 2025 | -71.88 Mn |
| Sep 30, 2025 | -110.92 Mn |
| Sep 30, 2025 | -110.92 Mn |
| Jun 30, 2025 | -106.30 Mn |
| Jun 30, 2025 | -106.30 Mn |
| Mar 31, 2025 | -80.40 Mn |
| Mar 31, 2025 | -80.40 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Sep 30, 2024 | -83.77 Mn |
| Sep 30, 2024 | -83.77 Mn |
| Jun 30, 2024 | -52.25 Mn |
| Jun 30, 2024 | -52.25 Mn |
| Mar 31, 2024 | -44.30 Mn |
| Mar 31, 2024 | -44.30 Mn |
| Dec 31, 2023 | -33.80 Mn |
| Dec 31, 2023 | -33.80 Mn |
| Sep 30, 2023 | -33.20 Mn |
| Sep 30, 2023 | -33.20 Mn |